Review
Aug 2026
Targeting TDP-43 in sporadic amyotrophic lateral sclerosis
Key biological mechanisms underlying TDP-43 pathology, emerging therapeutic strategies, and evolving approaches to clinical trial design and biomarker development are examined.
C. Estévez-Fraga, R. Álvarez-Velasco, Tariq Afroz et al.
· Journal of Neurology · 1 citation